Bubs Australia Ltd. (AU:BUB) has released an update.
Bubs Australia Limited has reached a pivotal point in its clinical trial by enrolling the 400th infant, marking a significant step towards securing permanent market access in the U.S. Upon the FDA’s expected approval in October 2025, Bubs aims to finalize its position as the leading goat milk formula brand in the United States. The company has been building a trust-based relationship with American families since first importing its formulas during the 2022 shortage, under the ‘Operation Fly Formula’ program.
For further insights into AU:BUB stock, check out TipRanks’ Stock Analysis page.
